Literature DB >> 14575625

Beta-adrenergic Receptor Blockers in Heart Failure.

Wendy M. Book1, Brenda J. Hott.   

Abstract

Congestive heart failure is a progressive disease with high morbidity and mortality if left untreated. Standard therapy for patients with systolic left ventricular dysfunction now includes angiotensin-converting enzyme inhibitors and beta blockers. beta Blockers have been demonstrated to decrease mortality, reduce hospitalizations, improve functional class, decrease left ventricular dimensions, and improve ejection fraction in several large-scale, randomized, placebo-controlled trials. In addition to reducing deaths due to progressive heart failure, beta blockers also reduce the incidence of sudden death. Therapy with beta blockers can successfully be initiated in most patients with heart failure if recommended titration schedules are followed. beta Blockers are an important component of medical therapy for all stages of heart failure.

Entities:  

Year:  2003        PMID: 14575625     DOI: 10.1007/s11936-003-0037-5

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  34 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 2.  Carvedilol.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

3.  Acute hemodynamic and neurohumoral effects of pindolol: a beta-adrenoceptor antagonist with high intrinsic sympathomimetic activity in patients with dilated cardiomyopathy.

Authors:  P A Majid; J Niznick; S Nishizaki; W M Morris; M J Sole
Journal:  J Cardiovasc Pharmacol       Date:  1987-09       Impact factor: 3.105

4.  Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.

Authors:  M Packer; G V Antonopoulos; J A Berlin; J Chittams; M A Konstam; J E Udelson
Journal:  Am Heart J       Date:  2001-06       Impact factor: 4.749

5.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

6.  Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.

Authors:  M Metra; R Giubbini; S Nodari; E Boldi; M G Modena; L Dei Cas
Journal:  Circulation       Date:  2000-08-01       Impact factor: 29.690

7.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Authors:  C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

8.  Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.

Authors:  C Maack; T Elter; G Nickenig; K LaRosee; M Crivaro; A Stäblein; H Wuttke; M Böhm
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

9.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

10.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.